Cargando…
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study
(1) Background: The clinical implications of COVID-19 outbreaks following SARS-CoV-2 vaccination in immunocompromised recipients are a worldwide concern. Cancer patients on active treatment remain at an increased risk of developing breakthrough infections because of waning immunity and the emergence...
Autores principales: | Nelli, Fabrizio, Fabbri, Agnese, Virtuoso, Antonella, Giannarelli, Diana, Giron Berrios, Julio Rodrigo, Marrucci, Eleonora, Fiore, Cristina, Schirripa, Marta, Signorelli, Carlo, Chilelli, Mario Giovanni, Primi, Francesca, Pessina, Gloria, Natoni, Federica, Silvestri, Maria Assunta, Ruggeri, Enzo Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217296/ https://www.ncbi.nlm.nih.gov/pubmed/37232844 http://dx.doi.org/10.3390/curroncol30050386 |
Ejemplares similares
-
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
por: Nelli, Fabrizio, et al.
Publicado: (2023) -
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
por: Nelli, Fabrizio, et al.
Publicado: (2022) -
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study
por: Ruggeri, E.M., et al.
Publicado: (2021) -
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
por: Nelli, F., et al.
Publicado: (2022) -
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
por: Nelli, F., et al.
Publicado: (2022)